Education ▼

SPECIALTY TOPICS

CURRENTLY VIEWING
Chronic Lymphocytic Leukemia

Breast Cancer

Gastrointestinal Cancer

Colorectal Cancer

Ovarian Cancer

Prostate Cancer

Precision Medicine in Oncology^®

Neoadjuvant HER2+

More >>

Chronic Lymphocytic Leukemia

Novel Agents, Combos Transforming Treatment in MCL and CLL

James N. Gerson, MD, discusses exciting updates in mantle cell lymphoma and chronic lyphocytic leukemia and other potentially practice-changing trials on the horizon.
Read More >>

Amid Explosion of Targeted Agents, FCR Retains a Role in CLL Paradigm

Breakthrough Therapies Enrich Evolving CLL Paradigm

Secondary Cancer Risk Remains an Unresolved Issue in CLL

SOHO 2019: Novel Combos Are Shaking Up the CLL Landscape

SOHO 2019: Duvelisib Dosing Modification Does Not Compromise Efficacy in Heavily Pretreated CLL/SLL

View More Stories >>

View Conference Coverage

2019 Lynn Sage Breast Cancer Symposium

2019 ESMO Congress

17th International Myeloma Workshop

2019 Society of Hematologic Oncology Annual Meeting

2019 World Conference on Lung Cancer

Dr. Gerson on Targeted Therapy Versus Chemotherapy in CLL

Dr. Mato on Utilizing CAR T Cells in CLL

Impact of BTK Inhibition on Monocytic Myeloid-Derived Suppressor Cells in CLL

Dr. Eradat Discusses Data With Acalabrutinib in CLL

Dr. Smith on Utilizing Lenalidomide in CLL

Dr. Eradat on the CAPTIVATE Trial in CLL

OncLive houses thousands of videos that provide updates and information.
See more Videos

CLL: Practical Advice on Selecting and Managing Therapy

Acalabrutinib's Role in Treating Chronic Lymphocytic Leukemia

Venetoclax + Obinutuzumab: Impact on CLL Management

Frontline Therapy in CLL: Combination Strategies and MRD

Stratifying Patients With CLL to Frontline Therapy

Ibrutinib's Role as Frontline Therapy in CLL

OncLive houses thousands of videos that provide updates and information.
See more Videos

BTK Inhibitors in Chronic Lymphocytic Leukemia

Genomic Profiling in Chronic Lymphocytic Leukemia

Venetoclax-Based Regimens as First-Line Therapy in CLL

$Relapsed/Refractory CLL: Evaluating Other Novel Agents$

$Novel Approaches to Treating Relapsed/Refractory CLL$

$Continuing Therapy in Relapsed/Refractory CLL$

OncLive houses thousands of videos that provide updates and information.
See more Videos

Featured Programs

Other Promising Strategies in CLL

This expert panel discussion led by William Wierda, MD, focuses on promising strategies available for the treatment of chronic lymphocytic leukemia. Dr. Wierda is joined in this discussion by Steven Coutre, MD; Matthew S. Davids, MD, MMSc; Nicole Lamanna, MD; and Shuo Ma, MD, PhD.

View Now

The Use of Novel PI3K Inhibitors in CLL

In this segment William Wierda, MD, PhD, leads a panel discussion regarding the use of novel PI3K inhibitors in chronic lymphocytic leukemia.

View Now

Featured Video

Dr. Esteva on the Future of Biosimilars in Breast Cancer

Francisco J. Esteva, MD, PhD, director, breast medical oncology program, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, discusses the future use of biosimilars in breast cancer within the United States. View now

FDA Approval in Myeloma, Label Update in HER2+ Breast Cancer, Breakthrough Status in Prostate Cancer, and More